Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 43 min ago
Peer-reviewedCC BYFrontiers in pharmacology

Saroglitazar protects against cadmium-induced hepatorenal injury in rats by suppressing NF-κB and upregulating Nrf2.

  • Ahmed Alanazi1
  • Hoda E Kafl1
  • Dalia H El-Kashef1
  • Ghada M Suddek1
  1. 1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
Read full textPDFDOICite

Abstract

Introduction

Cadmium (Cd) toxicity is one of the major public health problems because of its long half-life (10-30 years). Exposure to Cd can cause toxicity that affects several organs, including the liver and the kidney. Saroglitazar is highlighted in this study as a potential preventative medication against hepatic-renal damage induced by Cd in rats.Methods

Cd (3 mg/kg) was injected for five successive days to induce hepatic and renal damage. Saroglitazar (2 and 4 mg/kg/day) was given orally for five successive days concurrently with Cd.Results

Saroglitazar effectively improved hepatic and renal function and structure. In the meantime, saroglitazar mitigated the oxidative stress caused by Cd; it increased the level of reduced glutathione (GSH) and the activity of superoxide dismutase (SOD) and decreased malondialdehyde (MDA) content. Saroglitazar-treated groups showed a significant reduction in hepatic and renal nuclear factor kappa B (NF-κB), tumor necrosis factor (TNF)-α, and interleukin-6 (IL-6). Furthermore, saroglitazar pretreatment significantly increased nuclear factor erythroid 2-related factor 2 (Nrf2); furthermore, there was a marked reduction in the expression of caspase-3 in both hepatic and renal tissues.Conclusion

Collectively, saroglitazar showed a protective effect against Cd-induced hepatorenal injury in rats.

Related

  1. Inhibition of PCSK9 protects against myocardial ischemia-reperfusion injury by suppressing ferroptosis via negative regulation of the P65/MMP9 pathway
    Jianan Xu, Shaohui Gao, Xuan Jiang +7
    Scientific ReportsPeer-reviewedCC BYFull textGeneral medicineDOAJ
  2. Luteolin protects against cholestasis by suppressing hepatocyte apoptosis through direct PI3K binding and AKT activation
    Xingliang Zhao, Yingchong Xu, Hongyan Liang +5
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefEurope PMC
  3. SGLT2i protects against myocardial I/R-induced coronary microvascular injury by inhibiting glycocalyx degradation
    Xiaoru Huang, Yunqi Jiang, Xinye Xu +2
    BMC MedicinePeer-reviewedCC BY 4.0General medicineCrossref
  4. Perioperative sophocarpine protects against testicular ischemia/reperfusion injury by blocking JNK/p38 signaling
    Pengyu Jia, Ziyue Ma, Lei Du +5
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textObstetrics, gynaecology & paediatricsCrossref
  5. Maternal vaccination with capsular polysaccharide bioconjugates protects against murine Klebsiella pneumoniae neonatal sepsis
    Paeton L. Wantuch, Jessica Tung, Lloyd S. Robinson +5
    Science advancesPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@article{alanazi2026saroglitazar,
  title = {{Saroglitazar protects against cadmium-induced hepatorenal injury in rats by suppressing NF-κB and upregulating Nrf2.}},
  author = {Ahmed Alanazi and Hoda E Kafl and Dalia H El-Kashef and Ghada M Suddek},
  journal = {Frontiers in pharmacology},
  year = {2026},
  month = oct,
  doi = {10.3389/fphar.2026.1916439},
  url = {https://europepmc.org/article/MED/42898561},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Saroglitazar protects against cadmium-induced hepatorenal injury in rats by suppressing NF-κB and upregulating Nrf2.
AU  - Ahmed Alanazi
AU  - Hoda E Kafl
AU  - Dalia H El-Kashef
AU  - Ghada M Suddek
PY  - 2026
DA  - 2026/10/05
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2026.1916439
UR  - https://europepmc.org/article/MED/42898561
AB  - Introduction  Cadmium (Cd) toxicity is one of the major public health problems because of its long half-life (10-30 years). Exposure to Cd can cause toxicity that affects several organs, including the liver and the kidney. Saroglitazar is highlighted in this study as a potential preventative medication against hepatic-renal damage induced by Cd in rats.Methods  Cd (3 mg/kg) was injected for five successive days to induce hepatic and renal damage. Saroglitazar (2 and 4 mg/kg/day) was given orally for five successive days concurrently with Cd.Results  Saroglitazar effectively improved hepatic and renal function and structure. In the meantime, saroglitazar mitigated the oxidative stress caused by Cd; it increased the level of reduced glutathione (GSH) and the activity of superoxide dismutase (SOD) and decreased malondialdehyde (MDA) content. Saroglitazar-treated groups showed a significant reduction in hepatic and renal nuclear factor kappa B (NF-κB), tumor necrosis factor (TNF)-α, and interleukin-6 (IL-6). Furthermore, saroglitazar pretreatment significantly increased nuclear factor erythroid 2-related factor 2 (Nrf2); furthermore, there was a marked reduction in the expression of caspase-3 in both hepatic and renal tissues.Conclusion  Collectively, saroglitazar showed a protective effect against Cd-induced hepatorenal injury in rats.
SN  - 1663-9812
ER  -